Literature DB >> 18085994

Genomic landscapes of cancers: prospects for targeted therapies.

Fonnet E Bleeker, Alberto Bardelli.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18085994     DOI: 10.2217/14622416.8.12.1629

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  6 in total

1.  Pharmacogenomics, evidence, and the role of payers.

Authors:  P A Deverka
Journal:  Public Health Genomics       Date:  2009-02-10       Impact factor: 2.000

2.  Contribution of the OBSCN nonsynonymous variants to aspirin exacerbated respiratory disease susceptibility in Korean population.

Authors:  Jeong-Hyun Kim; Byung-Lae Park; Charisse Flerida A Pasaje; Yongha Kim; Joon Seol Bae; Jong Sook Park; Soo-Taek Uh; Yong-Hoon Kim; Mi-Kyeong Kim; Inseon S Choi; Sang Heon Cho; Byoung Whui Choi; InSong Koh; Choon-Sik Park; Hyoung Doo Shin
Journal:  DNA Cell Biol       Date:  2012-01-17       Impact factor: 3.311

3.  Somatic mutation signatures of cancer.

Authors:  Stephen R Piccolo; Lewis J Frey
Journal:  AMIA Annu Symp Proc       Date:  2008-11-06

4.  Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.

Authors:  Han Kiat Ho; Boon Tin Chua; Winnie Wong; Kah Suan Lim; Vivian Teo; Hooi-Tin Ong; Xiao Chen; Wei Zhang; Kam M Hui; Mei Lin Go; Axel Ullrich
Journal:  Mol Oncol       Date:  2014-05-02       Impact factor: 6.603

5.  Multiplicity: an organizing principle for cancers and somatic mutations.

Authors:  Lewis J Frey; Stephen R Piccolo; Mary E Edgerton
Journal:  BMC Med Genomics       Date:  2011-06-29       Impact factor: 3.063

6.  Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort.

Authors:  Somayye Taghvaei; Farzaneh Sabouni; Zarrin Minuchehr
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.